Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying science to provide medical solutions to patients and future generations. Almirall is focused on fighting skin health diseases and helping people feel better.
Almirall also supports healthcare professionals in their continuous improvement, and provides innovative solutions where they are needed.
“The healthcare sector is only now beginning to realize the potential of cannabinoid-based medicines and this is provoking significant, fast-paced changes in terms of regulation and access to these new treatments. As pioneers in this field, partnering with Cannabis Europa allows us to collaborate with experts from across Europe in our quest to ensure this evolving landscape will allow for equitable access to evidence based licensed cannabinoid-based medicines for the right patient at the right time.” — Monique Hull, Global Marketing Lead at Almirall.
The company was founded almost 75 years ago and is headquartered in Barcelona, Spain. Almirall is also listed on the Spanish Stock Exchange under the ticker ALM. In 2018, the company’s total revenues exceeded €810 million euros. Almirall has become a key source of value creation for society thanks to its commitment to its principal shareholders, and its decision to help others by understanding their challenges and using science to provide solutions for real life.
Almirall operates a total staff of around 1,800 employees, of which 270 are dedicated to the company’s expert pharmaceutical research and development programme. Almirall continues to support cannabinoid-based research, in order to ensure that patients can have access to effective, evidence-based medicinal treatments.
Join us on February 10th at the Intercontinental Hotel in Madrid to discover the latest news from the European cannabis sector, learn from our world-renowned speakers and network with industry-leading professionals.